Current status and future directions in food protein-induced enterocolitis syndrome: An NIAID workshop report of the June 22, 2022, virtual meeting.

Autor: Nowak-Wegrzyn A; Department of Pediatrics, Hassenfeld Children's Hospital, NYU Grossman School of Medicine, New York, and the Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland; Department of Pediatrics, Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Anna.nowak-wegrzyn@nyulangone.org., Sicherer SH; Department of Pediatrics, Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Akin C; Department of Medicine, University of Michigan, Division of Allergy and Clinical Immunology, Ann Arbor, Mich., Anvari S; Division of Immunology, Allergy and Retrovirology, Texas Children's Hospital, Baylor College of Medicine, Houston, and Texas Children's Hospital, William T. Shearer Center for Human Immunobiology, Houston, Tex., Bartnikas LM; Department of Medicine, Division of Immunology, Boston Children's Hospital, Boston, and Harvard Medical School, Boston, Mass., Berin MC; Department of Medicine, Division of Allergy/Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill., Bingemann TA; Department of Allergy, Immunology and Rheumatology and the Department of Pediatric Allergy and Immunology, University of Rochester School of Medicine, Rochester, NY., Boyd S; Stanford University School of Medicine, Palo Alto, Calif., Brown-Whitehorn T; Division of Pediatric Allergy and Immunology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pa., Bunyavanich S; Department of Pediatrics, Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Cianferoni A; Division of Pediatric Allergy and Immunology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pa., du Toit G; Department of Women and Children's Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, and the Children's Allergy Service, Evelina London Children's Hospital, Guy's and St Thomas' Hospital, London, United Kingdom., Fortunato JE; Gastroenterology, Hepatology and Nutrition, Northwestern University Feinberg School of Medicine, Chicago, Ill., Goldsmith JD; Department of Pathology, Boston Children's Hospital, Boston, and Harvard Medical School, Boston, Mass., Groetch M; Department of Pediatrics, Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Leonard SA; Division of Pediatric Allergy & Immunology, Rady Children's Hospital San Diego, University of California, San Diego, Calif., Rao M; Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, and Harvard Medical School, Boston, Mass., Schultz F; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Rockville, Md., Schwaninger JM; International FPIES Association (IFPIES), Point Pleasant, NJ., Venter C; Children's Hospital Colorado, University of Colorado, Denver, Colo., Westcott-Chavez A; IFPIES, Point Pleasant, NJ., Wood RA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md., Togias A; Allergy, Immunology and Transplantation, NIAID, National Institutes of Health, Rockville, Md.
Jazyk: angličtina
Zdroj: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Nov 07. Date of Electronic Publication: 2024 Nov 07.
DOI: 10.1016/j.jaci.2024.10.022
Abstrakt: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated gastrointestinal food allergy characterized by delayed, protracted vomiting and accompanied by lethargy and pallor, usually 1 to 4 hours after ingesting the food allergen. The pathophysiology of FPIES remains unknown, and currently there are no diagnostic biomarkers available to assess disease activity or its resolution. Over the last 2 decades, FPIES has become increasingly recognized in both pediatric and adult patients. Forty years after the initial FPIES description, the first FPIES code appeared in the International Classification of Diseases, Tenth Revision (ICD-10), and the first international consensus guidelines for the diagnosis and management of FPIES were published. On June 22, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) held its first virtual multidisciplinary workshop on FPIES. Various clinical and translational aspects of FPIES as well as important areas of unmet needs were discussed as priorities for future research during this 2-day virtual workshop. Our report provides a summary of content of the workshop, including updated literature on the topic areas, and also provides critical commentary on the state of FPIES.
Competing Interests: Disclosure statement The workshop was supported by funds from the Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID). The authors of this report are responsible for its content. Statements in the report do not necessarily represent the official views of or imply endorsement by the National Institutes of Health, NIAID, the Department of Health and Human Services, or any other agency of the United States government. Disclosure of potential conflict of interest: A. Nowak-Wegrzyn reports research support from Alladapt Immunotherapeutics, DBV Technologes, Siolta Therapeutics, and Regeneron; speaking fees from Nestlé, Danone, and Thermo Fisher; consulting fees from Aquestive; royalties from UpToDate; and service as associate editor for Annals of Allergy, Asthma & Immunology, chair of the ABAI board of directors, director of the AAAAI board, and chair of the medical advisory board of the International FPIES Association. S. H. Sicherer reports royalty payments from UpToDate and from Johns Hopkins University Press; grants to his institution from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research and Education (FARE), and Pfizer; and personal fees from the American Academy of Allergy, Asthma & Immunology as deputy editor of the Journal of Allergy and Clinical Immunology: In Practice outside the submitted work. C. Akin reports consultancy and research support from Blueprint Medicine and Cogent for tyrosine kinase inhibitor therapies in mastocytosis outside the submitted work. S. Anvari receives funding from NIH NIAID and DBV Technologies for contracted work outside of the submitted work; and reports consultancy with DBV Technologies. L. M. Bartnikas receives research support from NIH NIAID, the International FPIES Association (IFPIES), and the Myles & Gertrude Hanson Foundation. M. C. Berin reports compensation for service on the scientific advisory board for Enterome. T. A. Bingemann reports service on the board of directors of the American Board of Allergy and Immunology and the board of regents for the American College of Allergy, Asthma and Immunology; is a member of the executive committee for AAP’s Section of Allergy and Immunology; has been a speaker for Sanofi; has been a consultant for ALK, Bryn, and Aimmune; and has served as principal investigator on a Novartis trial. G. du Toit reports grants from NIH NIAID, FARE, MRC & Asthma UK Centre, Action Medical Research, and the National Peanut Board; is scientific advisory board member for Aimmune; is investigator on pharma-sponsored peanut allergy immunotherapy studies (Aimmune, DBV Technologies, and Novartis); and is joint director of The Food Allergy Immunotherapy Centre. M. Groetch reports royalties from UpToDate, FARE, and the Academy of Nutrition and Dietetics; and serves on the medical advisory board of IFPIES, as a senior advisor to FARE, as a health sciences advisor for the American Partnership for Eosinophilic Disorders, and on the editorial board of Journal of Food Allergy. F. Schultz is employed by IFPIES; and is a consultant for Aijinomoto Cambrooke. C. Venter reports grants from Reckitt Benckiser; and personal fees from Reckitt Benckiser, Nestlé Nutrition Institute, Danone, Abbott Nutrition Else Nutrition, Sifter, Owyn, and Before Brands outside the submitted work. A. Westcott-Chavez is employed by IFPIES. R. A. Wood reports research support from Takeda Pharmaceuticals outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
(Copyright © 2024 American Academy of Allergy, Asthma & Immunology. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: